We focus on the role of CD8 + Treg cell in Intravenous methyl-prednisolone (IVMP) pulse therapy in forty patients with active Class III/IV childhood lupus nephritis (LN) with heavy proteinuria. IVMP therapy for five days. From peripheral blood mononuclear cells (PBMCs) and renal tissues, we saw IVMP therapy definitely restoring both CD4 
Introduction
Childhood lupus nephritis (LN) remains a significant therapeutic challenge due to its complex etiopathogenesis and unpredictable course. Systemic lupus erythematosus (SLE) is characterized by autoantigen-deriven interactions between autoreactive Th and B cells, spawning production of somatically mutated IgG autoautibodies against apoptotic nuclear antigens (Ags) [1, 2] , pathogenic IgG autoantibodies belonging to Th1-or interferon gamma (IFNr)-dependent subclass contributing differentiation of autoimmune Th cell with concomitant decrease in regulatory T (Treg) cells [3] . Although immunological defect of SLE is complex. Treg cells play a vital role in autoreactive cell expansion [3] . CD4 + CD25 + Treg cells have potent immunosuppressive function and contribute to immunological self-tolerance in SLE [4, 5] . Recent studies demonstrate Treg cell number as inversely correlated with disease activity, a mechanism that may benefit treatment of LN [4, 5] . CD8 + T cells are also abnormal in SLE patients, less competent in cytotoxic activity [6] . CD8 + Treg cells expressing transcription factor Foxp3 with regulatory function in maintaining self-tolerance have recently been identified [7] . CD8 + CD25
+

FoxP3
+ T cells can be generated by continuous antigen (Ag) stimulation [7, 8] . CD8 + Treg cells were first identified in human tonsils; upon in vitro activation, FoxP3 + CD8 + Treg cells were shown to inhibit T cell proliferation directly [8] . CD8 + Treg cells seem to perform a regulatory function to limit autoimmune disease in experimental models [7] [8] [9] [10] [11] [12] . Human CD8 + Treg cells are implicated in autoimmune disorders: e.g., multiple sclerosis, inflammatory bowel disease [13] . Suppressive CD8 + Foxp3 + Treg cells appear after T cell receptor stimulation, suppressing cellular proliferation of CD4 + naïve and effector T cells via cell-cell contact lysis or soluble factors like IL-10 and TGF-b [7, [14] [15] . Systemic immunization with allergen in mice induces CD8
+ Treg cells to inhibit allergic diarrhea, suggesting their pivotal role in limiting autoimmune disease [16] . CD8 + CD25 + Treg cells have suppressive ability typically associated with CD4 + Treg [17] [18] [19] [20] [21] . Interaction between subsets of Treg cells that protect against autoimmune diseases remains unclear. Foxp3-expressing CD8 + T proved vital for CD4 + CD25
+
Treg cells induced by a tolerogenic peptide to suppress murine lupus [22] . Animal models of SLE suggest defective CD8 + Treg cells associated with LN [23] and induction of CD8 + Treg cells with immune tolerance of lupus mice [24] . Complement activation enhance leukocyte infiltration and production of pro-inflammatory cytokines in the kidney [25] . Active LN in children always had high level of complement activation [26, 27] . Clinically, kidney involvement in LN may vary from mild hematuria or proteinuria to acute or chronic kidney disease. Renal pathology can have a broad range of Class I-VI. Class III and IV both were diffuse proliferative glomerulonephritis [28] .
While conventional treatment with intravenous methylprednisolone (IVMP) suppresses disease activity and complement activation in children with LN, some patients still develop progressive renal injury; some who respond to treatment remain at risk of relapse [29] . Yet no study rates IVMP effect on Treg cells to maintain immune tolerance from active Class III and IV LN. This study focuses on the role of CD8 + Treg cells in IVMP therapy, 40 LN patients receiving IVMP and 10 historical control patients only treated with oral prednisolone. Our results provide evidence that CD8 + Treg cells play an important role of inducing treatment immune modulation by IVMP.
Results
Clinical response of LN patients after IVMP pulse therapy
Median duration between LN diagnosis and time of study was 314 (range: 0 = 1148) days. LN was the first manifestation in 37 of 40 patients; for the rest, thrombocytopenia and anemia were the first manifestations of SLE. Descriptors of SLEDA present at the time of blood withdrawal before IVMP in study population included arthritis, hematuria, proteinuria, new molar rash, low complement, mucosal ulcer, increased DNA binding, hemolytic anemia, thrombocytopenia and leucopenia (Table 1) . There was a sharp rise of SLEDAI score two weeks after IVMP treatment (Table 2) . At study entry, mean serum C3 level was 63.5621.1 mg/dl, C4 level 11.166.7 mg/dl and anti-dsDNAAb was 258.1642.2 U/ml. Increase in both C3 and C4, decrease in anti-dsDNA Ab with daily urine protein loss and activity of LN by SLEDAI-2k in childhood LN before IVMP were significantly higher than those two weeks after IVMP ( Table 2 ). All patients showed improved two weeks after IVMP pulse therapy. (Fig. 1a) for surface markers and intracellular FoxP3 expression simultaneously in PBMCs following anti-CD3 mAb stimulation (5 mg/ml) and IL-2 (10 U/ml) for five days in each group. As shown in Table 3 and Figure 1 
Increase of CD4
Discussion
There exist several hypotheses for the IVMP therapy mechanism: (1) immune ablation eliminates autoreactive T cell clone; (2) autoreactive T cell clones are rendered tolerant; (3) regulatory networks control autoreactive T cells and complement activation. In fact, upon immune reconstitution, default mechanism of the immune system is self-tolerance; Treg function plays a crucial role. Most studies of Treg cells in human SLE focus on CD4 + Treg, with results conflicting [30] but suppressive function of CD4 + Treg cells impaired [31] . Recent evidence shows corticosteroids influencing regulatory cell population or even generating Treg cells [32] . Besides SLE patients, treatment with glucocorticoids yields increase in Treg cells and FoxP3 levels in patients with asthma [33] , immune thrombocytopenia purpura patients [34] and multiple sclerosis [35] .
Observation in murine SLE indicates CD8 + Tregs playing a lead role in disease activity [36] . We found significantly low number of both CD4 + T proliferation [37] . These indicate a different mechanism in IVMP therapy to obtain clinic efficacy; understanding those mechanisms may enhance LN therapy. Table 2 shows most post-IVMP LN patients improving SLEDAI score. CD8 + Treg cells from these patients showed strong suppressive function both in vitro and in vivo. Auto-antibodies against C1q are directed against a highly functional molecule with vital roles in autoimmunity. We proved strong correlation between occurrence of anti-C1q antibodies in Class III/IV LN. Increasing evidence shows inactive classic complement pathway definitely improved in Class III/IV LN, and CD8 + Treg cells seem to play a suppressing complement activation in classic pathway.
Earlier studies showed up-regulation of Th1 cytokine IL-2 and IFN-c together with decreased production of Th2 cytokine IL-4 up-regulating autoantibody production by B cells and associated with disease activity [38] . Administration of anti-IFN-c antibodies [39] + T cells back to PBMCs can reconstitute this Ab production [5] . Prior studies show, in contrast to normal T cells, SLE patients' T cell response to nucleosomal histone peptide epitopes by producing intracellular IFN-r and inducing anti-DNA autoantibodies [40] . Our study proves, before [46] . Our prior study showed that cytotoxic CD8+ Treg cells increasing expression of granzyme B may induce apoptosis of CD4+ CD45RO+ memory T cells during allergy immunotherapy [7] . Treg cells can utilize granzyme B to suppress immune responses against tumors and elevated granzyme B(+)/Foxp3(+) cell ratio in tumor cells had a better outcome [47, 48] In sum, number of CD4 
Materials and Methods
Ethics Statement
Criteria for exclusion were previous cyclophosphamide or mycophendate motifil, calcineurin inhibitors, or rituximab.
Clinical data including serum creatinine (Cr), glomerular filtration rate (GFR), 24-hour (hr) proteinuria were recorded. Disease activity was assessed by a SLE Disease Activity Index (SLEDAI) score -2k (SLEDAI-2k), validated for use in children [29, 41] . LN activity was defined by renal score of SLEDAI-2k [49, 50] . Patients with SLEDAI ,3 were considered inactive (remission), those with SLEDAI §8 active [51] . Intervention strategy was based on IVMP pulse therapy and prednisolone. IVMP group patients all received pulse therapy (15-20 mg/kg and maximum with 1 g/ day, for 5 days) followed by oral prednisolone 1 mg/kg of body weight and mycophenolate mofetil (cellcept) 280 mg/m 2 of body surface area twice a day. Doses could be tapered off for proteinuria ,1 g/d. Oral prednisolone dosage was tapered to 0.75 mg/kg during the second week, to 0.5 mg/kg during the third. Patients took this dose with subsequent tapering during follow-up as clinically allowed. All subjects provided written informed consent by patients and parents prior to inclusion. The study was approved by the Institutional Review Board of China Medical University Hospital (DMR97-IRB-259). Table 1 . Class III or IV LN was classified according to the International Society of Nephrology and Renal Pathology Society [52] . A total of 12 LN patients had no treatment before because of first diagnosis at study entry, and 28 with heavy proteinuria were in relapse at time of the study, median duration of disease was 44 (range 14-112) months.
Design and Participants
Peripheral blood mononuclear cells (PBMC) were obtained from LN before (Day 0) and after (Day 6) IVMP pulse therapy. Follow-up serum C3, C4, anti-dsDNA Ab levels and 24 hours daily urine protein were calculated two weeks after IVMP pulse therapy. Serum C3 and C4 levels were determined by nephelometry, serum IgG anti-dsDNA Ab by fluorescence enzyme immunoassay (Pharmacia, Uppsah, Sweden). Plasma samples were evaluated by commercially ELISA kits by assay procedure for the presence of anti-C1q antibody (Orgentec Diagnostika GmbH, Mainz, Germany), assays performed in duplicate. Ten children with similar age distribution and no history of autoimmune disease undergoing examination for health evaluation were recruited as healthy controls. All patients enrolled in each group completed this study, with approval of the institutional ethical review board.
Renal evaluation and histopathologic assessment
Renal evaluation at the outset and repeat renal biopsies were performed at 3-6 month follow-up, biopsy samples graded according to the World Health Organization (WHO) classification system [36] . Addition, activity and chronicity indices were determined [52] . 
Cell isolation and cell culture
PBMCs were isolated by Ficoll-paque gradient centrifuge (Pharmacia, Uppsala, Sweden), 1610 6 cells were cultured and divided on 96-well culture plates in RPMI-1640 culture medium [7] . In some experiments, CD8
+ or CD4 + cells were depleted directly from PBMCs, using microbeads as per manufacturer's protocol (BD Biosciences, San Diego, CA) [7] . CD8 + CD25 + T cells were isolated by CD8 + T cell enrichment kit followed by separation with CD25 microbeads (BD Biosciences). Purity of CD8 + CD25 + T cells population analyzed by flow cytometry exceeded 95%. CD4
hi Treg cells from normal subjects were purified by EPICS Altra high-speed cell sorter (Beckman Coulter, Miami, FL) and used as positive controls for intracellular Foxp3 expression [7] .
Flow cytometry
Cells were stained for 30 minutes with fluorescein-conjugated mAbs. CD8 +
CD25
+ Treg cells were permeated, then stained with PE-conjugated, anti-Foxp3 mAb (BD Biosciences). For intracellular IL-10 and Granzyme B cytokine staining, PBMCs were activated with phorbol meristate acetate (PMA) (10 ng/ml) and ionomycin (1 mg/ml) for the last 5 hours of incubation period and brefeldin A (10 mg/ml) (Sigma-Aldrich, St Louis, MO) was added for final hours of stimulation. Cells were fixed, permeated, and stained via standard procedures (eBioscience, San Diego, CA), then analyzed by FACS scan flow-cytometer (FC500, Beckman Coulter, Fullerton, CA), acquiring 10,000 events [7] .
Cell proliferation assay
PBMCs and CD8
+ depleted-PBMCs were labeled with 5 mM CFSE (Invitrogen, Carlsbad, CA) for 15 minutes at 37uC. Cells were washed twice and stimulated with either anti-human CD3 mAb (1 mg/ml) for five days. For CFSE-suppression assay, CD8 + CD25 + Tregs were added to culture autologus, CD8-depleted and CFSE-labeled PBMCs at 1:10 ratio, proliferation of CD4 + T cells rated by CFSE fluorescence with flow cytometric analysis [7] . + were analyzed for IFN-r production by flow cytometry [7] .
Detection of IFN-r response in CD4 T cells response to autoepitopes
Peptides
All peptides were synthesized by F-moc chemistry, their purity checked by amino acid analysis, as per manufacturer's protocol (Chiron mimotopes and New England Peptide).
Detection of CD4
+ CD45RO + T cell apoptosis
Purified CD8
+ CD25 + Treg cells isolated from LN patients were added to autologus CD25 + depleted-PBMCs from lupus nephritis before IVMP and healthy subjects for five days. Apoptosis rate of CD4 + CD45RO + T cells was obtained by flow cytometry after labeling DNA strand breaks, using a TUNEL kit (Mebstain kit, Lminy, Frcmceu), data confirmed by Annexin V-PI kit (BD Biosciences) [7] .
siRNA transfection
One pair of small-interfering RNAs (siRNA) was synthesized by Invitrogen Life Technology (Invitrogen, Ltd., Taiwan). Peripheral blood CD8
+ CD25 + T cells were isolated and pretreated with nucleosomal histone peptide epitope with IL-2 (10 U/ml) for three days, treated with dexamethasone on the third day, then transfected with FoxP3 siRNA (20 mM) using Lipofectamine PNAiMAX (Invitrogen Life Technology). After 48 hours, proteins were extracted for granzyme B western blot, cellular lysates prepared as described previously [7] . Blots were blocked with 4% BSA for 1 h at 22.2uC and probed with rabbit anti-human Ab against granzyme B (Abcam, Abgent, San Diego, CA) and atubulin (Sigma) (1/1000), as visualized by ECL using Kodak X-OMATLS film (Eastman Kodak), quantitative data obtained by computing densitometer and Image Quant software.
Renal Histopathology
Formalin-fixed sections were stained with hematoxylin and eosin, periodic acid Schiff, periodic acid-silver methenamine, and Masson's trichrome [53] . Pathology of glomerular cross-sections (gcs)/kidney was scored on a four-point scale: 0, normal (35-40 cells/gcs); 1, few lesions with slight proliferative change and mild hypercellularity (41-50 cell/gcs); 2, moderate hypercellularity (51-60 cells/gcs); 3, severe hypercellularity (.60 cell/gcs). Minimal change nephrotic syndrome specimens served as normal controls.
Double Immunohistochemistry
Formalin-fixed and paraffin-embedded blocked renal biopsy specimens were treated according to protocol described previously [38] . Primary antibodies used were anti-mouse monoclonal Ab. + cell counts were calculated as positive cells per HPF at X400 magnification from 10 randomly chosen fields within the same section of the kidney biopsy specimen from an individual patient [53] .
Statistical Analysis
Statistical analysis was performed with commercially available SPSS 12.0 software (SPSS Inc., Chicago, IL), continuous variables expressed as mean 6 standard deviation (SD), intergroup comparison by Student t-test, quantitative PCR data analyzed via non-parametric Wilcoxon paired test. Significant differences were defined as p,0.05, group comparison by one-way ANOVA, p-value,0.05 considered significant. 
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